Drug Combination Details
| General Information of the Combination (ID: C06709) | |||||
|---|---|---|---|---|---|
| Name | Noscapine | + | Temozolomide + Bis-chloroethylnitrosourea + Cisplatin | ||
| Click to Show/Hide the Each NP or Drug Information of This Combination | |||||
| Name | Noscapine NP Info | Drug Info | |||
| Structure |
|
|
|||
| Name | Drug Info | ||||
| Structure |
|
|
|||
| Name | Drug Info | ||||
| Structure |
|
|
|||
| Disease |
Brain cancer
[ICD-11: 2A00]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Expression | PARP1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | U87/DK | CVCL_3428 | Glioblastoma | Homo sapiens | ||
| In-vivo Model | For a xenograft model, 4*106 U87MG cells were inoculated subcutaneously into one flank of 5-6 weeks old, female nude mice. | |||||
| Experimental
Result(s) |
NOS synergistically potentiated the efficacy of FDA-approved anti-cancer drugs against human glioblastoma cells, thereby allowing them to be used at lower doses and hence minimizing their toxic side effects. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Synergistic suppression of noscapine and conventional chemotherapeutics on human glioblastoma cell growth. Acta Pharmacol Sin. 2013 Jul;34(7):930-8. | |||
